GLP-1s in children, Syntis Bio, Vera: Readout Newsletter
National Biotech Reporter Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways…
Novo Nordisk rebrands to ‘Novo’ under CEO Mike Doustdar
People walk past a sign for Novo Nordisk’s annual general meeting at the entrance to the venue in…
Engineered bacteria speed rock weathering for carbon removal
Weathering rocks naturally pull carbon dioxide from the atmosphere, but the process is too slow to make…
Recipients of gene-edited pig kidneys successfully receive human organs
When doctors think about sticking an organ from another animal into a person, one of their many questions…
Lilly to buy Merida Biosciences for up to $2.88 billion in autoimmune drug push
Eli Lilly and Company’s logo is displayed during a press conference in Houston, Texas, U.S., Sept. 23, 2025.…
Paternal sperm epigenetics may help explain early pregnancy loss
When a pregnancy ends early and unexplained, the search for answers usually begins with the mother. Lacey Luense,…
A scoping review on the mental health harms of LLM-based chatbots
Weizenbaum, J. ELIZA—a computer program for the study of natural language communication between man and machine. Commun. ACM…
Bioformulations of Entrophospora lutea enriched with biostimulants for growth promotion and control of Rhizoctonia root rot in lupine
Delaeter, M., Magnin-Robert, M. & Randoux, B. Arbuscular mycorrhizal fungi as biostimulant and biocontrol agents: a review. Microorganisms…
Amylyx endocrine drug succeeds in key study for low blood sugar
Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected…
Eli Lilly, Novo Nordisk earnings show widening divide in GLP-1 market
The Eli Lilly and Novo Nordisk logos. Mike Blake | Tom Little | Reuters The diverging paths of…
Eli Lilly (LLY) earnings Q2 2026
Eli Lilly on Wednesday reported second-quarter earnings and revenue that blew past estimates and hiked its full-year sales outlook,…
Insilico Medicine highlights AI-powered biological target discovery for rare sinonasal cancer
Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced the publication of a collaborative…